Robert Atchinson

Robert Atchinson has an estimated net worth of $4.51 Billion. This is based on reported shares across multiple companies, which include ORBCOMM Inc., HeartWare International, Inc., Royalty Pharma plc, Celanese Corp, SELECT COMFORT CORP, MULESOFT, INC, GCM Grosvenor Inc., Solaris Oilfield Infrastructure, Inc., HUBBELL INC, Protagonist Therapeutics, Inc, Mandalay Digital Group, Inc., PUMA BIOTECHNOLOGY, INC., Calithera Biosciences, Inc., CONCERT PHARMACEUTICALS, INC., Advaxis, Inc., Nexvet Biopharma plc, AMCI Acquisition Corp., AMAG PHARMACEUTICALS INC., East Resources Acquisition Co, ABEONA THERAPEUTICS INC., PACIFIC SUNWEAR OF CALIFORNIA INC, Vitae Pharmaceuticals, Inc, SMART BALANCE, INC., FIVE PRIME THERAPEUTICS INC, CARDIOME PHARMA CORP, Targanta Therapeutics Corp., GENEVA ACQUISITION CORP, EyePoint Pharmaceuticals, Inc., Solid Biosciences Inc., and Praxis Precision Medicines, Inc..

2015 was Robert Atchinson's most active year for acquiring shares with 26 total transactions. Robert Atchinson's most active month to acquire stocks was the month of September. 2017 was Robert Atchinson's most active year for disposing of shares, totalling 38 transactions. Robert Atchinson's most active month to dispose stocks was the month of March. 2020 saw Robert Atchinson paying a total of $84,000,000.00 for 46,015,330 shares, this is the most they've acquired in one year. In 2020 Robert Atchinson cashed out on 13,056,561 shares for a total of $333,391,124.70, their largest year based on trade value.